Evolocumab
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Metabolic Effects of Evolocumab and Atorvastatin
Conditions
Acute Metabolic Effects of Evolocumab and Atorvastatin
Trial Timeline
Feb 1, 2024 → Dec 1, 2025
NCT ID
NCT06140095About Evolocumab
Evolocumab is a phase 1 stage product being developed by Amgen for Acute Metabolic Effects of Evolocumab and Atorvastatin. The current trial status is unknown. This product is registered under clinical trial identifier NCT06140095. Target conditions include Acute Metabolic Effects of Evolocumab and Atorvastatin.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06140095 | Phase 1 | UNKNOWN |
| NCT04539223 | Approved | UNKNOWN |
| NCT03944577 | Phase 2 | Completed |
| NCT03331666 | Approved | Terminated |
| NCT03403374 | Approved | Completed |
| NCT03096288 | Approved | Completed |
| NCT03080935 | Phase 3 | Terminated |
| NCT02957604 | Pre-clinical | Terminated |
| NCT02624869 | Phase 3 | Completed |
| NCT02867813 | Phase 3 | Completed |
| NCT02585895 | Phase 3 | Completed |
| NCT02304484 | Phase 3 | Completed |
| NCT02275156 | Phase 1 | Completed |
| NCT01652703 | Phase 2 | Completed |
| NCT01624142 | Phase 2/3 | Completed |
| NCT01439880 | Phase 2 | Completed |
| NCT01380730 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Metabolic Effects of Evolocumab and Atorvastatin